超越欧洲药品预算的孤立思维。 - Suppr

Suppr

超能文献

Moving beyond the drug budget silo mentality in Europe.

作者信息

Drummond Michael, Jönsson Bengt

机构信息

Centre for Health Economics, University of York, York, UK.

出版信息

Value Health. 2003 Jul-Aug;6 Suppl 1:S74-7. doi: 10.1046/j.1524-4733.6.s1.8.x.

DOI:10.1046/j.1524-4733.6.s1.8.x

PMID:12846928

Abstract

摘要

相似文献

Moving beyond the drug budget silo mentality in Europe.

Value Health. 2003 Jul-Aug;6 Suppl 1:S74-7. doi: 10.1046/j.1524-4733.6.s1.8.x.

The drug budget silo mentality in Europe: an overview.

Value Health. 2003 Jul-Aug;6 Suppl 1:S1-9. doi: 10.1046/j.1524-4733.6.s1.1.x.

The drug budget silo mentality: the French case.

Value Health. 2003 Jul-Aug;6 Suppl 1:S10-9. doi: 10.1046/j.1524-4733.6.s1.2.x.

The drug budget silo mentality: the Dutch case.

Value Health. 2003 Jul-Aug;6 Suppl 1:S46-51. doi: 10.1046/j.1524-4733.6.s1.5.x.

Using disease management and market reforms to address the adverse economic effects of drug budgets and price and reimbursement regulations in Germany.

Value Health. 2003 Jul-Aug;6 Suppl 1:S20-30. doi: 10.1046/j.1524-4733.6.s1.3.x.

[Separate pharmaceutical budgets: skating on thin ice].

Ned Tijdschr Geneeskd. 2010;154(51-52):A3004.

Spending on pharmaceuticals in Italy: macro constraints with local autonomy.

Value Health. 2003 Jul-Aug;6 Suppl 1:S31-45. doi: 10.1046/j.1524-4733.6.s1.4.x.

Challenges to achieving value in drug spending in a decentralized country: the Spanish case.

Value Health. 2003 Jul-Aug;6 Suppl 1:S52-63. doi: 10.1046/j.1524-4733.6.s1.6.x.

Management of cost and utilization of pharmaceuticals in Germany.

Health Policy. 1997 Sep;41 Suppl:S45-53. doi: 10.1016/s0168-8510(97)00052-3.

UK budgetary systems and new health-care technologies.

Value Health. 2003 Jul-Aug;6 Suppl 1:S64-73. doi: 10.1046/j.1524-4733.6.s1.7.x.

引用本文的文献

Switch from public to private retail pharmaceutical expenditures: evidence from a time series analysis in Italy.

BMJ Open. 2022 Mar 8;12(3):e055421. doi: 10.1136/bmjopen-2021-055421.

Combating antibiotic resistance using guidelines and enhanced stewardship in Kenya: a protocol for an implementation science approach.

BMJ Open. 2020 Mar 31;10(3):e030823. doi: 10.1136/bmjopen-2019-030823.

Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates.

Appl Health Econ Health Policy. 2018 Dec;16(6):803-817. doi: 10.1007/s40258-018-0419-1.

Role of the Pharmacoeconomic Aspects in the Clinical Management of Hypertension.

High Blood Press Cardiovasc Prev. 2016 Jun;23(2):151-4. doi: 10.1007/s40292-016-0152-5. Epub 2016 May 9.

Controversies in Antimicrobial Stewardship: Focus on New Rapid Diagnostic Technologies and Antimicrobials.

Antibiotics (Basel). 2016 Jan 14;5(1):6. doi: 10.3390/antibiotics5010006.

Use of economic evaluation in decision making: evidence and recommendations for improvement.

Drugs. 2010 Oct 22;70(15):1917-26. doi: 10.2165/11538120-000000000-00000.

Cost-containment as part of pharmaceutical policy.

Pharm World Sci. 2005 Jun;27(3):144-8. doi: 10.1007/s11096-005-6953-6.

Applying health technology assessment to pharmaceutical care: pitfalls and future directions.

Pharm World Sci. 2005 Apr;27(2):73-5. doi: 10.1007/s11096-004-4098-7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Moving beyond the drug budget silo mentality in Europe.

Value Health. 2003 Jul-Aug;6 Suppl 1:S74-7. doi: 10.1046/j.1524-4733.6.s1.8.x.

The drug budget silo mentality in Europe: an overview.

Value Health. 2003 Jul-Aug;6 Suppl 1:S1-9. doi: 10.1046/j.1524-4733.6.s1.1.x.

The drug budget silo mentality: the French case.

Value Health. 2003 Jul-Aug;6 Suppl 1:S10-9. doi: 10.1046/j.1524-4733.6.s1.2.x.

The drug budget silo mentality: the Dutch case.

Value Health. 2003 Jul-Aug;6 Suppl 1:S46-51. doi: 10.1046/j.1524-4733.6.s1.5.x.

Using disease management and market reforms to address the adverse economic effects of drug budgets and price and reimbursement regulations in Germany.

Value Health. 2003 Jul-Aug;6 Suppl 1:S20-30. doi: 10.1046/j.1524-4733.6.s1.3.x.

[Separate pharmaceutical budgets: skating on thin ice].

Ned Tijdschr Geneeskd. 2010;154(51-52):A3004.

Spending on pharmaceuticals in Italy: macro constraints with local autonomy.

Value Health. 2003 Jul-Aug;6 Suppl 1:S31-45. doi: 10.1046/j.1524-4733.6.s1.4.x.

Challenges to achieving value in drug spending in a decentralized country: the Spanish case.

Value Health. 2003 Jul-Aug;6 Suppl 1:S52-63. doi: 10.1046/j.1524-4733.6.s1.6.x.

Management of cost and utilization of pharmaceuticals in Germany.

Health Policy. 1997 Sep;41 Suppl:S45-53. doi: 10.1016/s0168-8510(97)00052-3.

UK budgetary systems and new health-care technologies.

Value Health. 2003 Jul-Aug;6 Suppl 1:S64-73. doi: 10.1046/j.1524-4733.6.s1.7.x.

引用本文的文献

Switch from public to private retail pharmaceutical expenditures: evidence from a time series analysis in Italy.

BMJ Open. 2022 Mar 8;12(3):e055421. doi: 10.1136/bmjopen-2021-055421.

Combating antibiotic resistance using guidelines and enhanced stewardship in Kenya: a protocol for an implementation science approach.

BMJ Open. 2020 Mar 31;10(3):e030823. doi: 10.1136/bmjopen-2019-030823.

Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates.

Appl Health Econ Health Policy. 2018 Dec;16(6):803-817. doi: 10.1007/s40258-018-0419-1.

Role of the Pharmacoeconomic Aspects in the Clinical Management of Hypertension.

High Blood Press Cardiovasc Prev. 2016 Jun;23(2):151-4. doi: 10.1007/s40292-016-0152-5. Epub 2016 May 9.

Controversies in Antimicrobial Stewardship: Focus on New Rapid Diagnostic Technologies and Antimicrobials.

Antibiotics (Basel). 2016 Jan 14;5(1):6. doi: 10.3390/antibiotics5010006.

Use of economic evaluation in decision making: evidence and recommendations for improvement.

Drugs. 2010 Oct 22;70(15):1917-26. doi: 10.2165/11538120-000000000-00000.

Cost-containment as part of pharmaceutical policy.

Pharm World Sci. 2005 Jun;27(3):144-8. doi: 10.1007/s11096-005-6953-6.

Applying health technology assessment to pharmaceutical care: pitfalls and future directions.

Pharm World Sci. 2005 Apr;27(2):73-5. doi: 10.1007/s11096-004-4098-7.